RecruitingPhase 1NCT07489482

A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection

A Randomized, Parallel, Open-label Clinical Study on the Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects


Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

60 participants

Start Date

Apr 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-3167 Injection for people with diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-3167 Injection

SHR-3167 injection, different specifications.


Locations(1)

Xiangya Hospital, Central South University

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07489482


Related Trials